GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (OSL:PCIB) » Definitions » Beta

PCI Biotech Holding ASA (OSL:PCIB) Beta : 1.21 (As of Dec. 12, 2024)


View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-12-12), PCI Biotech Holding ASA's Beta is 1.21.


PCI Biotech Holding ASA Beta Historical Data

The historical data trend for PCI Biotech Holding ASA's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA Beta Chart

PCI Biotech Holding ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.75 -0.37 -0.24 1.76 1.26

PCI Biotech Holding ASA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23 Jun24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.76 2.19 1.96 1.26 1.21

Competitive Comparison of PCI Biotech Holding ASA's Beta

For the Biotechnology subindustry, PCI Biotech Holding ASA's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PCI Biotech Holding ASA's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's Beta distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's Beta falls into.



PCI Biotech Holding ASA Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


PCI Biotech Holding ASA  (OSL:PCIB) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


PCI Biotech Holding ASA Beta Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


PCI Biotech Holding ASA Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.

PCI Biotech Holding ASA Headlines

No Headlines